The PROTEK Duo has been developed for use as single cannula for both venous drainage and reinfusion of blood through an internal jugular vein during extracorporeal life support (ECLS) procedures.
The new cannula has been designed to solve two major roadblocks, which have prevented VV ECLS therapy from becoming a new standard of care.
These include the difficulty of initiating and maintaining a patient on VV ECLS support and suboptimal gas exchange rates with currently available devices.
CardiacAssist president and CEO John Marous said that TandemHeart has been focused on the treatment of heart failure since the company’s inception in 1996.
"The US launch of PROTEK Duo with our TandemHeart platform is propelling our company into a new era, creating innovative products for both heart & respiratory failure," Marous added.
CardiacAssist has also developed FDA-cleared and CE-marked short-term extracorporeal circulatory support platform, which can be used by interventional cardiologists and cardiac surgeons.
